Ketamine Therapy Blog — Mental Health Insights & Treatment Guides

Expert insights on ketamine therapy, depression, anxiety, PTSD, and mental health treatment — updated regularly by the Isha Health clinical team.

All Mental Health Science of Ketamine Ketamine Therapy Basics News Inside Isha

GLP-1 Agonists and Mental Health: What the Research Says

Apr 4, 2026Mental Health

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are being studied for effects on depression, anxiety, and addiction. Here's what the research shows so far.

Guide to using a superbill for ketamine therapy insurance reimbursement at Isha Health

Ketamine Therapy & Insurance: How to Use a Superbill

Apr 1, 2026

Isha Health is out-of-network, but you may still get reimbursed. Learn how a superbill works, what to expect from your insurer, and how to submit your claim

Ashwagandha for Depression: Dosage, Research, and What to

Mar 31, 2026Mental Health

What does the research say about ashwagandha for depression? We cover the Lopresti 2017 study, recommended dosage ranges, the BDNF connection, standardized extracts, and realistic timelines.

Person in a calm room during an at-home ketamine therapy session for PTSD

Ketamine Therapy for PTSD: How It Works, What to Expect

Mar 30, 2026

Can ketamine treat PTSD? A physician's guide to the research, how it compares to EMDR, and what at-home ketamine therapy looks like.

Ashwagandha Side Effects: What to Know Before You Start

Mar 24, 2026Mental Health

A clinical guide to ashwagandha side effects, drug interactions, contraindications, liver safety concerns, and how to choose a quality supplement.

Ashwagandha vs Antidepressants: Can a Supplement Replace

Mar 17, 2026Mental Health

Can ashwagandha replace antidepressants like SSRIs? We compare mechanisms, evidence strength, and risks, and explain why stopping prescribed medication for a supplement can be dangerous.

Is Ashwagandha Good for Anxiety? What the Evidence Says

Mar 10, 2026Mental Health

Does ashwagandha actually help with anxiety? We review the clinical evidence, including key studies on cortisol reduction and GABAergic activity, dosage recommendations, and who should avoid it.

Ketamine psilocybin neuroplasticity comparison - how psychedelics reshape the brain

Ketamine vs. Psilocybin for Neuroplasticity: How

Feb 27, 2026Research

A landmark Cell Reports study found that psychedelics including ketamine and psilocybin promote structural and functional neural plasticity. Here is how they compare and what it means for treatment.

Ketamine treatment response predictors - biomarkers and clinical factors

Who Responds Best to Ketamine? What Research Says About

Feb 23, 2026Research

Research is identifying clinical predictors of ketamine response in treatment-resistant depression, including BMI, family history, and anxiety features. Here is what the evidence shows.

Ketamine gut brain axis microbiome research - emerging connections

Ketamine and the Gut-Brain Axis: Could Your Microbiome

Feb 17, 2026Research

Emerging research suggests ketamine may influence gut microbiome composition, and that the gut-brain axis could play a role in its antidepressant effects. Here is what we know so far.

MDMA therapy PTSD research - Phase 3 clinical trial results

MDMA-Assisted Therapy for PTSD: What the Phase 3 Trial

Feb 9, 2026Research

A Phase 3 trial published in Nature Medicine found that MDMA-assisted therapy produced significant improvements in severe PTSD. Here is a detailed look at the study and what it means.

Psilocybin depression trial - COMPASS Pathways Phase 2b results

Psilocybin for Depression: What the COMPASS Pathways

Feb 2, 2026Research

The largest psilocybin trial for treatment-resistant depression, published in the New England Journal of Medicine, showed significant results at the 25mg dose. Here is what the data reveals.

Page 1 of 16